H.C. Wainwright assumed coverage of InflaRx (IFRX) with a Buy rating and $6 price target The company has an approved asset whose entrance onto the market is a validation of the anti-C5a/C5aR strategy in inflammation, the analyst tells investors in a research note. The firm says InflaRx is “flying under the radar with investors.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IFRX: